Instrument Inactif

Communiqués Genzyme Corporation

Actions

US3729171047

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

28/06/11	SANOFI : Sanofi/Mipomersen efficace dans l'hypercholestérolémie	RE
04/04/11	Genzyme : succès de l'OPE de Sanofi-aventis.

Communiqués

28/06/11	GENZYME CORP.GNL : Mipomersen Data Presented at European Atherosclerosis Society Congress	PU
07/03/11	GENZYME CORP.GNL : Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares	BU
01/03/11	GENZYME CORP.GNL : Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group	BU
28/02/11	GENZYME CORP.GNL : Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program	BU
18/02/11	GENZYME CORP.GNL : Three-Year Data from Phase 2 Trial of Genzyme Gaucher Disease Oral Compound Suggest Sustained or Further Improvement Across All Endpoints	BU
16/02/11	GENZYME CORP.GNL : Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year	BU
01/02/11	GENZYME CORP.GNL : Genzyme Completes Sale of Diagnostics Business to Sekisui Chemical Co.	BU
31/01/11	GENZYME CORP.GNL : Genzyme Will Allow Sanofi-Aventis to Conduct Due Diligence	BU
20/01/11	GENZYME CORP.GNL : Genzyme to Build Additional Plant to Support Growth of Myozyme® and Lumizyme®	BU
11/01/11	GENZYME CORP.GNL : Genzyme Financial Recovery Continues in Fourth Quarter	BU
10/01/11	GENZYME CORP.GNL : Genzyme Statement on Discussions With Sanofi-Aventis	BU
20/12/10	GENZYME CORP.GNL : Genzyme Details Market Potential of Alemtuzumab for MS	BU
13/12/10	GENZYME CORP.GNL : Genzyme to Hold Investor Event on Alemtuzumab	BU
13/12/10	GENZYME CORP.GNL : Genzyme Reiterates Board's Position on Sanofi-Aventis Tender Offer	BU
01/12/10	GENZYME CORP.GNL : Genzyme Completes Sale of Genetic Testing Business to LabCorp	BU
24/11/10	GENZYME CORP.GNL : Genzyme Successfully Meets First Milestones of FDA Consent Decree	BU
18/11/10	GENZYME CORP.GNL : Genzyme Announces Agreement to Sell Diagnostics Business to Sekisui Chemical Co.	BU
08/11/10	GENZYME CORP.GNL : Genzyme Responds to Sanofi-Aventis Letter	BU
22/10/10	GENZYME CORP.GNL : Genzyme Details Financial Recovery and Other Factors Driving Company's Value	BU
21/10/10	GENZYME CORP.GNL : Genzyme Announces Webcast of Analyst and Investor Event	BU
20/10/10	GENZYME CORP.GNL : Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML	BU
20/10/10	GENZYME CORP.GNL : Genzyme Reports Financial Results for the Third Quarter of 2010	BU
14/10/10	GENZYME CORP.GNL : Genzyme's Alemtuzumab Shows Sustained Reduction in Relapses and Disability in Five-Year Review of MS Patients from Phase 2 Trial	BU
13/10/10	GENZYME CORP.GNL : Genzyme Announces Upcoming Analyst and Investor Events	BU
07/10/10	GENZYME CORP.GNL : Genzyme Board Unanimously Rejects Sanofi-Aventis Tender Offer	BU